Finasteride
PharmaceuticalPreclinicalAlso known as: Propecia, Proscar, Fincar, Finpecia, MK-906, N-tert-butyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, Type II 5α-reductase inhibitor
Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss). Developed by Merck in the 1980s and first approved by the FDA in 1992 as Proscar (5mg/day) for BPH, finasteride was subsequently approved in 1997 as Propecia (1mg/day) for male-pattern hair loss after trials demonstrated that lower doses effective for scalp DHT suppression maintained efficacy for hair regrowth with fewer systemic effects.
Overview
At A Glance
Finasteride's mechanism is mechanistically straightforward but systemically consequential: it is a potent, selective, irreversible inhibitor of 5α-reductase type II (and, to a lesser extent, type III), which are the enzymes responsible for converting testosterone (T) to dihydrote…
Mechanism of Action
Finasteride's mechanism is mechanistically straightforward but systemically consequential: it is a potent, selective, irreversible inhibitor of 5α-reductase type II (and, to a lesser extent, type III), which are the enzymes responsible for converting testosterone (T) to dihydrotestosterone (DHT) in androgen-sensitive peripheral tissues. Understanding why this simple pharmacologic action produces such extensive clinical effects — and such controversial side-effect profile — requires examining the full scope of DHT physiology and 5α-reductase biology in human tissues.
The 5α-reductase enzyme family: Three isoforms have been characterized in humans, each encoded by a separate gene, each with distinct tissue expression and functional roles. Type I (SRD5A1) is predominantly expressed in skin (sebaceous glands), liver, and non-genital hair follicles; it has higher pH optimum (pH 7-8) and lower substrate affinity for testosterone (Km ~1-5 μM). Type II (SRD5A2) is the dominant isoform in androgen-sensitive reproductive tissues — prostate, seminal vesicles, epididymis, genital skin, and scalp hair follicles susceptible to androgenetic alopecia. It has lower pH optimum (pH 5-5.5) and higher substrate affinity (Km ~0.1-1 μM), making it the primary enzyme converting T to DHT under physiologic conditions in these tissues. Type III (SRD5A3) was characterized more recently and is expressed broadly, including in brain, prostate cancer cells (particularly castration-resistant prostate cancer), and other tissues. Finasteride inhibits type II strongly (IC50 ~3-5 nM) and type III moderately, with minimal activity against type I. This selectivity distinguishes it from dutasteride, which is a broad-spectrum inhibitor of all three isoforms with higher potency.
Inhibition mechanism — not reversible competition: Finasteride is a mechanism-based (suicide) inhibitor of 5α-reductase type II. Unlike competitive reversible inhibitors that simply occupy the active site without being modified, finasteride forms a covalent adduct with the NADPH cofactor within the enzyme's active site (NADP-dihydrofinasteride complex) that is essentially irreversibly bound to the enzyme and requires new enzyme synthesis for recovery of function. This means enzyme inhibition persists well beyond plasma drug clearance — plasma finasteride half-life is ~6-8 hours, but functional DHT suppression persists for days. Steady-state DHT suppression is achieved within 2-4 weeks of daily dosing and dissipates over weeks after discontinuation as new enzyme is synthesized. The irreversible-inhibition mechanism also explains why once-daily dosing produces consistent effect despite short plasma half-life — the enzyme, not the drug, is the "reservoir."
Systemic DHT suppression with finasteride: At the 1mg/day dose used for hair loss, finasteride produces approximately 65-70% suppression of serum DHT and ~85% suppression of scalp DHT — reflecting the heavy contribution of type II activity to local DHT generation in scalp follicles. At the 5mg/day dose used for BPH, serum DHT suppression reaches ~70-75% and prostatic DHT suppression ~85-90%. The remaining DHT (~25-35% of baseline) is generated by type I and type III activity, which is not inhibited by finasteride. This contrasts with dutasteride (pan-5AR inhibitor) which suppresses serum DHT by ~95% and produces more complete prostatic and scalp DHT suppression but at the cost of broader tissue-level effects.
Reciprocal testosterone and estradiol changes: With DHT generation reduced, testosterone is "unshunted" from the 5α-reductase pathway, typically producing a ~10-20% increase in serum testosterone on finasteride. Because testosterone is aromatizable to estradiol via CYP19A1, this modest T increase produces a parallel ~5-15% increase in serum estradiol. These changes are modest in magnitude but may contribute to some finasteride side effects including gynecomastia (estradiol:testosterone ratio effects in breast tissue) and possibly mood changes. Individual response varies based on baseline steroid levels, body composition, aromatase expression, and genetic factors.
Hair follicle biology and finasteride efficacy: In androgenetic alopecia, genetically susceptible scalp follicles undergo progressive miniaturization driven by DHT binding to androgen receptors in dermal papilla cells, which triggers follicle cycling abnormalities — shortened anagen (growth) phase, prolonged telogen (resting) phase, and progressive reduction in follicle diameter and depth across successive cycles. This process converts terminal (thick, pigmented) scalp hairs to vellus-like (short, thin, unpigmented) hairs, eventually producing visible hair loss in the characteristic male-pattern distribution. Finasteride reduces scalp DHT by ~85%, halting the miniaturization process and allowing follicles that have not yet terminally atrophied to revert toward terminal morphology. Efficacy is greatest for hair stabilization (preventing further loss, achievable in 80-90% of treated men) and for early-to-moderate hair loss (Norwood 2-5); effect on extensive, longstanding hair loss (Norwood 6-7) is much more modest because terminal follicle loss is largely irreversible.
Prostate biology and finasteride efficacy: BPH involves stromal and epithelial hyperplasia in the prostatic transition zone, driven in part by persistent local DHT signaling. Finasteride-induced DHT suppression produces prostatic involution over months — characteristic time course is ~20% prostate volume reduction over 6-12 months, with associated improvement in urinary flow rate and lower urinary tract symptoms. Because the prostatic hyperplasia reflects tissue architectural changes, benefits require sustained treatment (continuation of finasteride); discontinuation reverses DHT suppression within weeks and prostate volume returns toward pretreatment levels over 6-12 months.
Neurosteroid implications — mechanistic basis for CNS effects and PFS: 5α-reductase isn't only active on testosterone — it also reduces progesterone to dihydroprogesterone, subsequently reduced to allopregnanolone (a potent positive allosteric modulator of GABA-A receptors producing anxiolytic, sedative, and neuroprotective effects); and reduces deoxycorticosterone to tetrahydrodeoxycorticosterone (THDOC), another GABA-A-positive neurosteroid. Brain tissue expresses 5α-reductase type I and type III (less type II), so finasteride has partial CNS effect on neurosteroid production. Melcangi et al. 2013 (PMID: 18424815) and subsequent studies have documented that finasteride use can reduce CNS allopregnanolone and related neurosteroids, and that these changes persist in some individuals after drug discontinuation. This is the leading mechanistic hypothesis for post-finasteride syndrome symptoms including depression, anxiety, cognitive complaints, and possibly sexual dysfunction unrelated to peripheral androgen levels. Why these neurosteroid changes persist long-term in some individuals — potentially involving epigenetic modifications in steroidogenic enzyme expression, or receptor/post-receptor adaptations — remains under active investigation.
Androgen receptor and post-receptor effects: With prolonged DHT suppression, some compensatory upregulation of androgen receptor expression occurs in target tissues, potentially partially offsetting the reduced ligand availability. This upregulation is incomplete and does not restore baseline DHT signaling, but contributes to the observation that finasteride effects plateau rather than progress indefinitely with continued dosing. Post-receptor, sustained DHT suppression alters expression of many androgen-regulated genes in prostate and skin, producing the integrated clinical effects on prostate volume and hair follicle function.
Pharmacokinetics and absorption: Oral finasteride has ~80% bioavailability with food having minimal impact. Peak plasma concentrations occur 1-2 hours post-dose, with plasma half-life ~6-8 hours in middle-aged adults (longer ~8-15 hours in elderly reflecting reduced hepatic clearance). Drug is ~90% protein-bound, extensively metabolized by CYP3A4 to inactive metabolites, and eliminated ~57% in feces and ~39% in urine. The relatively short plasma half-life contrasts with much longer functional effect duration (weeks) reflecting the irreversible enzyme inhibition mechanism. No dose adjustment required for mild-moderate renal impairment; caution in severe hepatic impairment.
Overview
Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss). Developed by Merck in the 1980s and first approved by the FDA in 1992 as Proscar (5mg/day) for BPH, finasteride was subsequently approved in 1997 as Propecia (1mg/day) for male-pattern hair loss after trials demonstrated that lower doses effective for scalp DHT suppression maintained efficacy for hair regrowth with fewer systemic effects. Finasteride remains one of only two FDA-approved oral therapies for androgenetic alopecia (the other being dutasteride, approved only in Korea and Japan for this indication). After 30+ years of clinical use and extensive post-marketing surveillance, finasteride has a strong efficacy profile for its labeled indications but remains one of the most controversial therapeutics in contemporary dermatology and urology due to the post-finasteride syndrome (PFS) debate — a collection of persistent sexual, cognitive, and psychological symptoms reported by some users after discontinuation that has prompted FDA labeling updates, ongoing research, and significant clinical-ethical discussion.
The mechanistic foundation is clear: 5α-reductase is a family of three isoenzymes (type I, II, III) that irreversibly convert testosterone to the more potent androgen dihydrotestosterone. DHT has roughly 3-5× higher androgen receptor binding affinity than testosterone and is the primary androgen driving prostate growth, hair follicle miniaturization in androgenetic alopecia, sebaceous gland activity, and some aspects of external male virilization. Type II 5α-reductase is the dominant isoform in prostate and hair follicles (its primary clinical target), while type I is dominant in skin, sebaceous glands, and liver; type III has been more recently characterized and is expressed in multiple tissues including brain. Finasteride selectively inhibits type II (primary) and type III (partial) isoforms with minimal effect on type I. This selectivity contrasts with dutasteride, which inhibits all three isoforms and produces more complete DHT suppression (~95% vs ~70% for finasteride) but at the cost of broader side-effect profile.
The clinical evidence base for finasteride is extensive and among the most rigorous in all of dermatology and urology. For BPH, the landmark 4-year PLESS trial (Proscar Long-term Efficacy and Safety Study, Gormley et al. 1992, NEJM PMID: 9471703, with extended outcomes in McConnell et al. 1998 PMID: 9475301) demonstrated that finasteride 5mg/day over 4 years reduced prostate volume by ~20%, improved urinary flow rate, reduced symptom scores, and — most critically — reduced the risk of acute urinary retention by 57% and BPH-related surgery by 55%. For hair loss, the key trials of Kaufman et al. 1998 (J Am Acad Dermatol PMID: 9685374) and Leyden et al. 1999 documented that finasteride 1mg/day over 1-2 years produced measurable hair count increases in ~83% of men, visible hair growth improvement in ~48%, and stabilization or improvement of androgenetic alopecia in ~90% of treated men, compared with progressive hair loss in most placebo controls. These findings have been reproduced across diverse populations (Sato et al. in Japan, Tosti et al. in Italy) and across multiple formulations.
Beyond its labeled indications, finasteride has been used off-label for: (1) female pattern hair loss in post-menopausal women (typically 2.5-5mg/day, evidence mixed but some positive trials in post-menopausal population without concomitant hyperandrogenism); (2) hirsutism and PCOS-related androgenic symptoms in women (with appropriate contraception given teratogenic risk); (3) prostate cancer chemoprevention (the PCPT trial, Thompson et al. 2003 NEJM PMID: 12824459, demonstrated finasteride reduced prostate cancer incidence by 25% but raised concerns about Gleason score upgrading that were ultimately revised after reanalysis); (4) hidradenitis suppurativa as adjunctive androgen-blockade therapy; and (5) transgender feminizing hormone therapy as an adjunct to estradiol for androgen suppression. For hair-loss dosing, topical finasteride formulations (0.25% solution, 0.1% gel) have emerged in the 2020s as an alternative delivery route attempting to preserve scalp efficacy while minimizing systemic exposure and side-effect risk — the comparative evidence (Piraccini et al. 2022, Ali et al. 2020 PMID: 32068269) suggests topical finasteride can produce hair count improvements comparable to oral 1mg/day with reduced systemic DHT suppression, though longer-term data and regulatory approvals vary by country.
The post-finasteride syndrome (PFS) controversy warrants explicit acknowledgment in any honest discussion of finasteride. Reports of persistent sexual dysfunction (PSD), neurologic/psychiatric symptoms, cognitive complaints, and somatic symptoms continuing weeks, months, or years after finasteride discontinuation have been collected through case series (Irwig 2011, 2012 PMIDs: 21067618, 22498944), post-marketing reports to the FDA MedWatch system, and patient-advocacy groups. The FDA updated the Propecia label in 2012 to include warnings about potential persistent sexual dysfunction, and subsequent label changes have added warnings regarding suicidal ideation and depression. Parallel labeling changes have been made in Europe, Canada, and the UK. The mechanistic hypothesis for PFS involves neurosteroid dysregulation — 5α-reductase is expressed in brain tissue and produces GABA-A-positive neurosteroids (allopregnanolone, pregnanolone, tetrahydrodeoxycorticosterone) from their steroid precursors, and finasteride-induced suppression of these neurosteroids has been documented (Melcangi et al. 2013 PMID: 18424815) to persist beyond drug cessation in some individuals. The clinical reality is that PFS is real for some users (well-documented persistent symptoms exist) but uncommon in randomized trials (most RCT side effects reverse on discontinuation) — individual susceptibility likely involves genetic, age-related, and possibly immunologic factors that remain incompletely characterized. Anyone considering finasteride should be aware of this possibility, discuss it with their prescriber, and have a clear plan for symptom monitoring and discontinuation criteria.
See also Dutasteride, Minoxidil, Saw Palmetto, DHEA, Testosterone, Pregnenolone, Ashwagandha, Clascoterone, and RU-58841 for adjacent androgen-pathway, hair-loss, and prostate-health compounds. This is educational content only and not medical advice — finasteride is a prescription medication with significant hormonal effects requiring physician supervision, baseline and follow-up monitoring, and informed consent regarding the full spectrum of potential effects including post-finasteride syndrome.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
Pregnancy — finasteride is Pregnancy Category X (contraindicated) due to teratogenic risk. Finasteride crosses the placenta and produces feminization of male fetal external genitalia through DHT deprivation during critical developmental windows. Women who are pregnant or may become pregnant must not take finasteride and should not handle crushed or broken tablets (intact tablets are coated and safe to handle). If a partner of a man taking finasteride becomes pregnant, the low finasteride exposure from semen (<7 ng/ejaculate) is below any demonstrated teratogenic threshold and condoms are not typically mandated, though some guidelines recommend them as a precaution.
Hypersensitivity to finasteride or its components — known allergic reaction to any 5α-reductase inhibitor.
Active liver disease — significant hepatic impairment (Child-Pugh B-C or elevated transaminases >3× ULN) requires careful individual assessment; routine use is relatively contraindicated.
Relative contraindications requiring careful discussion:
Pre-existing depression, anxiety, or psychiatric history — given the association with depression and suicidal ideation in post-marketing surveillance, users with significant mood disorder history should have explicit risk-benefit discussion before initiating, close monitoring on treatment, and low threshold for discontinuation if mood symptoms emerge. Some practitioners will decline to prescribe finasteride in men with active major depressive disorder or recent suicidality.
Pre-existing sexual dysfunction — men with baseline erectile dysfunction, low libido, or ejaculatory disorder may experience worsening on finasteride and may have difficulty distinguishing drug effect from baseline. Careful counseling and often preferential use of topical formulations are reasonable.
Planning pregnancy in the near term — women planning pregnancy within ~1 year should not use finasteride or should discontinue with sufficient washout (4-6 weeks covers plasma clearance; semen clearance is similar). Men planning conception should be aware that finasteride does not impair fertility in most men but can affect ejaculate volume and has theoretical spermatogenesis effects at high doses.
Suspected or diagnosed prostate cancer — finasteride suppresses PSA and can mask detection; in men with palpable prostate abnormalities or significantly elevated PSA, evaluation should precede initiation. In men with confirmed prostate cancer, finasteride is generally not used during active treatment without urologic oncologist direction.
Family history of male breast cancer — rare but reported in finasteride users; men with strong family history should have careful breast examination at baseline and periodically.
Elderly with polypharmacy — while finasteride has minimal drug interactions, elderly patients often have concurrent conditions (cardiovascular, renal, hepatic) that warrant complete review before adding another medication.
Situations requiring medical consultation before use:
Any psychiatric symptoms on treatment — new or worsened depression, anxiety, suicidal thoughts require immediate discontinuation and psychiatric evaluation. Do not persist through psychiatric side effects.
Breast changes — new lumps, nipple discharge, skin changes, or persistent breast tenderness require prompt evaluation to rule out breast cancer and to assess gynecomastia severity.
Persistent sexual dysfunction — does not resolve with brief drug holiday or dose reduction — warrants discontinuation and endocrine/urologic evaluation.
Urinary retention (in men with BPH) — sudden inability to urinate despite finasteride use warrants emergency evaluation.
Unexpected PSA rise on treatment — any increase in on-treatment PSA warrants urologic evaluation.
Legal and regulatory notes: Finasteride is a prescription medication in essentially all countries. It is not a controlled substance and is not restricted in competitive sport (unlike DHT itself or anabolic steroids). Some military and law-enforcement entry requirements may inquire about finasteride use — disclosure is generally recommended.
This is educational content only and not medical advice. Any use of finasteride for any indication warrants physician supervision, informed consent regarding the full spectrum of potential effects including post-finasteride syndrome, baseline assessment, and periodic monitoring. The decision to use or continue finasteride should involve clear-eyed assessment of individual risk tolerance, aesthetic/clinical priorities, and alternatives.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$39.99
—
1
1
topical
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
Finasteride Topical Solution 50mL | topical | 50mL bottle● In Stock | $39.99BEST | — |
Tracking since Apr 6, 2026 · 1 data point
Vendors Selling Finasteride
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Finasteride
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
How long until I see results from finasteride for hair loss?
Meaningful hair improvement from finasteride 1mg/day takes time. Expect minimal visible change in the first 3 months; early signs of stabilization by 4-6 months; measurable hair count and visible cosmetic improvement by 6-12 months; and peak benefit typically at 12-24 months. Initial 'shedding' during weeks 2-8 is common and is generally a positive sign (terminal hairs exiting phase before new growth). Do not judge efficacy before 6 months minimum; 12 months is a better evaluation point. Add topical minoxidil 5% from the start for optimal outcomes — the combination is superior to either alone (Kaufman 1998 PMID: 9685374; subsequent comparative trials).
What is post-finasteride syndrome and is it real?
Post-finasteride syndrome (PFS) describes persistent sexual, cognitive, and psychological symptoms — including persistent low libido, erectile dysfunction, genital sensory changes, depression, anxiety, cognitive fog, and somatic symptoms — that continue weeks to years after stopping finasteride in a subset of users. PFS is real: the FDA updated finasteride labeling in 2012 to include warnings about persistent sexual dysfunction, and subsequent updates added depression and suicidal ideation warnings. Case series (Irwig 2011, 2012 PMIDs: 21067618, 22498944) and patient registries have documented thousands of cases. However, epidemiology is debated — PFS incidence estimates range from <1% to ~3% of users, and no RCT has been specifically designed to quantify it. Mechanistic hypothesis involves persistent neurosteroid dysregulation (Melcangi 2013 PMID: 18424815) — 5α-reductase produces GABA-A-positive neurosteroids like allopregnanolone, and these can remain altered after drug cessation. Users should be aware, discuss with prescribers, and have a clear monitoring plan. If persistent symptoms develop after stopping, seek evaluation at a center familiar with PFS.
Finasteride vs dutasteride — which is better?
Finasteride inhibits 5α-reductase type II (~70% serum DHT suppression) while dutasteride inhibits types I, II, and III (~95% DHT suppression). For hair loss, meta-analyses (Gupta & Charrette 2014) show dutasteride produces modestly greater hair count improvement than finasteride (~1.5× increase) but with correspondingly higher sexual side effect rates. For BPH, the two have comparable efficacy with slight edge to dutasteride in prostate volume reduction. Practical considerations: finasteride has 30+ years of experience and broader FDA labeling including Propecia for hair loss; dutasteride is FDA-approved in the US only for BPH (not hair loss). Choose finasteride first for hair loss; consider dutasteride for inadequate response after 18+ months of comprehensive finasteride-based therapy. Do not combine them.
Can topical finasteride replace oral finasteride for hair loss?
Topical finasteride 0.25% solution applied twice daily produces hair count improvements comparable to oral finasteride 1mg/day in comparative trials (Ali 2020 PMID: 32068269; Piraccini 2022). Importantly, plasma DHT suppression with topical is ~30-40% versus ~70% with oral, which correlates with reduced sexual side effect reporting. Topical finasteride is approved in some European countries (Italy has an approved product) but in the US requires compounding pharmacy prescription. Reasonable first-line option for men concerned about oral side effects or wanting to minimize systemic exposure. Disadvantages: requires twice-daily application, somewhat more expensive when compounded, and long-term comparative safety data are still emerging.
Do I need to stop finasteride before prostate cancer screening?
No, but you must adjust PSA interpretation. Finasteride suppresses serum PSA by approximately 50%. Standard practice is to multiply the measured PSA by 2 after at least 6 months of finasteride therapy, using the doubled value for screening purposes. Establish an on-treatment PSA baseline at 6 months, and any subsequent rise from this baseline warrants urologic evaluation. This PSA correction is important — failing to adjust can mask prostate cancer detection. Inform your primary care physician and any urologist of finasteride use so that PSA interpretation is correctly adjusted. Never rely on absolute PSA values in finasteride users without the adjustment.
Does finasteride cause permanent sexual dysfunction?
For most users, sexual side effects from finasteride reverse within weeks of discontinuation. Trial data (Kaufman 1998 and extensions) show ~1-3% incidence of transient sexual side effects at 1mg/day (lower than at 5mg/day), with most resolving on continued dosing (tolerance) or upon discontinuation. However, a subset of users develop persistent sexual dysfunction lasting months to years after stopping — the 'PSD' component of post-finasteride syndrome (Irwig 2011 PMID: 21067618 documented mean 40-month symptom persistence in affected men). Incidence estimates for persistent sexual dysfunction vary (<1% to ~3% of users). Risk factors may include age at initiation (younger may be higher risk), duration of use, genetic/neurosteroid variation, and baseline sexual/psychiatric history. Anyone considering finasteride should be aware of this possibility. If sexual side effects develop and do not resolve with brief discontinuation, seek evaluation rather than persisting.
Can women use finasteride for hair loss?
Yes, but with important caveats. In pre-menopausal women of reproductive potential, finasteride is generally contraindicated due to teratogenic risk (feminization of male fetuses) unless absolutely reliable contraception is ensured. Post-menopausal women can use finasteride 2.5-5mg/day for female pattern hair loss with modest evidence of benefit (especially in those with hyperandrogenic features). Pre-menopausal women with PCOS or hyperandrogenism may use finasteride 2.5-5mg/day combined with reliable contraception (usually oral contraceptive) and often alongside spironolactone. Finasteride 1mg/day alone showed no significant efficacy in one pre-menopausal women's trial (Price 2000). Women should obtain dermatologic and endocrine evaluation before initiating, including baseline testosterone, DHEA-S, and thyroid labs to rule out other causes of androgenic alopecia. Never handle crushed or broken tablets during reproductive years.
Can I stop finasteride if I'm satisfied with my hair regrowth?
No — discontinuing finasteride will progressively reverse hair benefits over 6-12 months as DHT levels return to baseline and follicle miniaturization resumes. This is the nature of pharmacologic androgen blockade: the underlying genetic susceptibility to DHT-induced hair loss remains, and resumes when the block is removed. Men who have achieved hair benefit and want to maintain it need to continue finasteride indefinitely. This is a genuine long-term commitment that should be understood at initiation. If you decide to stop (for any reason including side effects, pregnancy planning with partner, or simply wanting to), expect gradual return to the pre-treatment trajectory. Some hair that had regrown may be lost; some stabilization benefit may persist if you had early-stage loss at initiation.
Is finasteride safe to take with testosterone replacement therapy (TRT)?
Yes, finasteride is pharmacologically safe with TRT — no contraindication exists, and many men use both. However, the physiologic combination is unusual: finasteride suppresses DHT (~70%) while TRT normalizes testosterone, creating a high T/low DHT state. Some practitioners consider this suboptimal because DHT has distinct biological roles (libido, brain function, skin, some cardiovascular effects), and its chronic suppression may contribute to the subset of TRT patients reporting persistent low libido or cognitive symptoms despite normalized T. Options: (1) continue finasteride to preserve hair; (2) stop finasteride on TRT and accept hair loss progression; (3) use topical finasteride for scalp effect with less systemic DHT reduction; or (4) switch to dutasteride if greater hair effect is desired despite broader systemic effects. No universal right answer — individual decision based on priorities. Monitoring: maintain E2 awareness (finasteride modestly increases aromatization; TRT also affects E2), and check DHT level if sexual symptoms emerge.
What should I do if I develop side effects on finasteride?
For mild transient side effects during the first 2-3 months (some libido change, mild mood shift, minor breast tenderness), many users tolerate continuation with symptomatic improvement over time. For any of the following, discontinue and seek medical evaluation: (1) New or worsened depression, anxiety, or suicidal thoughts; (2) Persistent sexual dysfunction not resolving within 2-4 weeks of brief trial discontinuation; (3) Gynecomastia (breast enlargement, nipple discharge, or new breast lumps); (4) Allergic reactions (rash, swelling); (5) Any persistent symptom that reduces quality of life. Do not persist through significant psychiatric side effects — the risk of post-finasteride syndrome increases with prolonged exposure in susceptible individuals. If symptoms persist after discontinuation for >4 weeks, this may represent post-finasteride syndrome and warrants evaluation at a center or practitioner familiar with PFS. Baseline documentation of sexual function and mood status before initiating makes side-effect recognition much clearer. Topical finasteride is a reasonable alternative for users who want hair benefit but cannot tolerate oral.
Research Tools
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsCompare Finasteride head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.